Juan Bustillo, MD
Psychiatry · Albuquerque, NMNPI 1700892445
Payments from drug & device makers
What this record shows
3 manufacturers reported payments, led by H2-pharma, LLC at 53.6% of the total. 2025 is the largest year on record at $198, 9.2 times the $22 reported in 2022.
Across 7 payments — averaging $39.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- H2-pharma, LLC$150
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$113
- E.r. Squibb & Sons, L.L.C.$17
Across 10 payments — averaging $17,039 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$105K
- Boehringer Ingelheim$45K
- Janssen Research & Development, LLC$20K
What the payments were for
- Speaking & faculty fees$15054%
- Food & beverage$13046%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| H2-pharma, LLC | 1 | $150 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $113 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
How this compares
$280 in reported general payments places this provider in the 65th percentile of 174 psychiatry providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 22 | $52,614 |
| Clozapine | 398 | $32,781 |
| Aripiprazole | 51 | $6,278 |
| Divalproex Sodium ErDivalproex Sodium | 45 | $3,592 |
| Divalproex Sodium | 38 | $1,606 |
| Phenelzine Sulfate | 12 | $1,137 |
| Clonazepam | 103 | $1,126 |
| Lorazepam | 38 | $758 |
| Trifluoperazine Hcl | 12 | $665 |
| Escitalopram Oxalate | 52 | $625 |
| Quetiapine Fumarate | 21 | $622 |
| Citalopram HbrCitalopram Hydrobromide | 31 | $583 |
| Duloxetine Hcl | 19 | $466 |
| Sertraline Hcl | 42 | $440 |
| Nortriptyline Hcl | 23 | $410 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Albuquerque
- Patricio EscalonaAlbuquerque$487K
- Mauricio TohenAlbuquerque$160K
- Shiva SharmaAlbuquerque$140K
- Javier VeraAlbuquerque$8K
- Nancy MartinAlbuquerque$6K
- Reuben SutterAlbuquerque$5K
- Swala AbramsAlbuquerque$3K
- David EarlAlbuquerque$3K
- Ronald RomanikAlbuquerque$2K
- Anthony HolzgangAlbuquerque$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.